Albert Schatz (scientist)

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Albert Schatz
Albert Schatz.jpg
Albert Schatz
Born
Albert Israel Schatz

(1920-02-02)2 February 1920
Died17 January 2005(2005-01-17) (aged 84)
CitizenshipUSA
Alma materRutgers University
Known forDiscoverer of streptomycin
Deprived of credit for discovery, leading to change in US laws
Spouse(s)Vivian Schatz (née Rosenfeld, married 1945)
ChildrenLinda Schatz
Diane Klein
Awards1994 Rutgers University Medal
Scientific career
FieldsMicrobiology
Science education
InstitutionsBrooklyn College
National Agricultural College in Doylestown
University of Chile
Washington University
Temple University
Author abbrev. (botany)A.Schatz

Albert Israel Schatz (2 February 1920 – 17 January 2005) was an American microbiologist and academic, who discovered the antibiotic streptomycin,[1] the first drug known to be effective for the treatment of tuberculosis.[2] He graduated from Rutgers University in 1942 with a bachelor's degree in soil microbiology, and received his doctorate from Rutgers in 1945. His PhD research led directly to the discovery of streptomycin.

Born to a family of farmers, Schatz was inspired to study soil science for its potential applicability to him to take up his family occupation. Topping his class at Rutgers in 1942, he immediately worked under Selman Waksman, then head of the Department of Soil Microbiology, but was drafted to the US Army to serve in the World War II. After a back injury led to his discharge from the army, he rejoined Waksman in 1943 as a PhD student. Working in isolation from others due to his use of the tuberculosis bacterium (Mycobacterium tuberculosis) he discovered a new antibiotic which he named "streptomycin" that was proven safe and effective against the tuberculosis bacterium and other Gram-negative bacteria. He also contributed to the discovery another antibiotic albomycin in 1947.

The discovery of streptomycin led to controversies over its royalties from commercial production, and the Nobel Prize. Unbeknownst to Schatz, Waksman had claimed financial benefits only for himself and the Rutgers Research and Endowment Foundation. A lawsuit granted Schatz 3% of the royalties and legal recognition as the co-discover. Then the 1952 Nobel Prize in Physiology or Medicine was awarded solely to Waksman explicitly "for his discovery of streptomycin,"[3] which The Lancet remarked as "a considerable mistake by failing to recognize Schatz's contribution."[4] As an act of goodwill, Schatz was honored with the Rutgers University Medal in 1994.

Early life and education[edit]

Schatz was born Norwich, Connecticut, US, and attended schools at Passaic, New Jersey. His parents, Russian Jewish émigré father Julius Schatz and English mother Rae Schatz were farmers. He entered the College of Agriculture at Rutgers State University of New Jersey in 1932. He completed the Bachelor of Science with honours in soil science in 1942, topping his class.[5] The day he received his result in May,[6] he joined as a postgraduate assistant to Selman Waksman who headed the Department of Soil Microbiology at Rutgers. Waksman had been directing a research program searching for new antibiotic compounds generated by microorganisms in ordinary soil since 1937, and his teams were to discover more than 10 such chemicals between 1940 and 1952. A fellow student, Doris Ralston, described Schatz as "A poverty-stricken, brilliant student who worked with a burning intensity."[5]

Schatz initially worked on the antibiotics, actinomycin, clavacin and streptothricin, which Waksman had developed. He observed that these compounds were too highly toxic in animals to be of any practical usage in humans.[6] After working for five months he was conscripted to the US Army in December 1942 during World War II. As a man with microbiology background, he was posted as a bacteriologist in the Medical Detachment of the Air Force, stationed in army hospitals in Florida.[7] He was discharged on 15 June 1943 due to back injury.[5]

With an option to work in a pharmaceutic company or pursue a PhD, Schatz chose the latter. He rejoined Waksman's lab from where he received a PhD in 1945 with the thesis "Streptomycin, an Antibiotic Produced by Actinomyces griseus."[6] His PhD work led to the discovery of the first antibiotic, streptomycin, that is effective against tuberculosis.[8]

Career[edit]

After leaving Rutgers in 1946, Schatz worked at Brooklyn College, and the National Agricultural College in Doylestown, Pennsylvania. Much of Schatz later work was on dentistry starting from 1953. While working as the Chief of the Division of Microbiology at the Philadelphia General Hospital, Schatz and his uncle Joseph J. Martin at the University of Pennsylvania Graduate School of Medicine developed a theory on the cause of tooth decay. The theory which they named "proteolysis-chelation theory" rooted in his original research in 1955.[7] The full framework of the theory was published in 1962.[9]

He became the Most Distinguished Professor of the Faculty of Chemistry and Pharmacy at the University of Chile from 1962 to '65,[10] then professor of education at Washington University from 1965 to '69, and professor of science education at Temple University from 1969 to '80.[2][11][12] At Chile, he continued to study the effects of fluoridation of drinking water.[7]

Discovery of streptomycin[edit]

On his return to Waksman's lab in 1943, Schatz offered to take on the search for an antibiotic effective against Gram-negative bacteria responsible for other penicillin-resistant diseases. There was no antibiotic then usable for the treatment of infections by Gram-negative bacteria – the only effective compound, streptothricin, although having low toxicity to leukocytes, was considered too toxic and too weak for clinical application.[13][14] At that time William Feldman at the Mayo Clinic had suggested that Waksman look for antibiotics that would fight tuberculosis. But Waksman had no intention because he was afraid to handle the deadly bacterium Mycobacterium tuberculosis, the causative pathogen of tuberculosis. When Schatz learned of this he insisted that he could work on a tuberculosis drug, to which Waksman agreed. Feldman gave him H-37, the most virulent tuberculosis bacterial strain in humans.[6]

Waksman made sure that Schatz worked alone and in the basement as the laboratory, and ordered Schatz that the bacterial samples should never leave the basement. Within three and a half months, Schatz had identified two related strains of bacteria (Streptomyces griseus) that belong to the group (order) Actinomycetes whose secretions stopped the growth of tubercle bacillus and several Gram-negative bacteria.[5] One strain came from a throat swab from a healthy chicken, the other from heavily manured field soil. He recollected his research saying:

During that time, I slept on a wooden bench in the laboratory. I drew a horizontal line with a red glassmarking pencil on the flasks from which I was distilling. If I was asleep when the liquid boiled down to the red mark, the night watchman woke me up and I added more liquid. This was during World War II when rationing was in effect. I therefore recycled organic solvents that I used in sufficiently large volumes to justify recycling. I worked day and night to produce that streptomycin because I wanted Feldman to do toxicity and in vivo tests as soon as possible, and because Waksman did not assign anyone to help me.[6]

In the afternoon of 19 October, he found that the tuberculosis bacteria were killed by his actinomycete extract, and gave the name "streptomycin"[6] following the scientific name of the source and the earlier antibiotic streptothricin discovered by Waksman and H. Boyd Woodruff in 1942.[15] The bacteria from chicken used in the experiment was provided by another researcher Doris Jones, and Elizabeth Bugie performed the antibacterial tests.[16] Schatz, Bugie and Waksman reported the discovery in the journal Experimental Biology and Medicine which published it on 1 January 1944.[17] The new compound was effective against both Gram-negative and Gram-positive bacteria, as well as the human strain of tuberculosis bacterium,[18][14] which is neither a Gram-negative or Gram-positivie species.[19] Their conclusion states:

Streptomycin, like streptothricin, possesses strong bactericidal properties, and preliminary experiments tended to indicate that the two substances are also comparable in their low toxicity to animals and in their in vivo activity. The various chemical and biological properties of streptomycin tend to point to this compound as one closely related to streptothricin; the fact that it differs from the latter in the nature of its antibacterial activity may indicate a closely related but not the same type of molecule.[17]

With his lab mates, Schatz announced on 4 August 1944 the effectiveness of streptomycin in vivo in experimental tuberculosis in mice.[20] He and Waksman reported that streptomycin is effective against different strains of tuberculosis bacterium and other related pathogens on 1 November 1944,[21] and published a series of papers on the production of streptomycin and related antibiotics the next year.[22][23][24] In 1946, they identified that only specific species of actinomycetes produce streptomycin.[25] Feldman and his team conducted the first clinical trial and toxicity tests at the Mayo Clinic in late 1944 and reported it in 1945.[26] The first individual treated was a 21-year-old girl who had advanced pulmonary tuberculosis and was given streptomycin on 20 November 1944.[27] By 1946, experiments conducted under the projects of Merck in the UK and USA had proven streptomycin's effectiveness against TB, bubonic plague, cholera, typhoid fever, and other penicillin-resistant diseases.[28][29][30] All the original samples in clinical trials were prepared by Schatz alone.[31]

Patent and controversy[edit]

Waksman knew that patenting streptomycin could be difficult because US patent law prohibited natural products and Schatz method had no particular novelty.[32] With the help of the Merck lawyers who had aided him patenting actinomycin and streptothricin, he argued that the new compound was chemically distinct from the natural compound in the bacteria. This convinced the patenting authority.[31][33]

In the patent agreement on 1 May 1946, both Schatz and Waksman agreed to receive a token $1.00 as recognition for being the inventors of the streptomycin production method, so that the beneficiary would be Rutgers and not individuals.[6] Schatz said he agreed to make streptomycin available as readily and inexpensively as possible, and he understood that the foundation, also, was to receive no profit from the discovery. At Waksman's request, Schatz signed over his right to royalties from the US streptomycin patent to the Rutgers Research and Endowment Foundation, and later signed over his foreign rights.[5] The US Patent Office granted U.S. Patent 2,449,866 "Improvement in Streptomycin and Processes of Preparation" to Schatz and Waksman on 21 September 1948 for the method of streptomycin preparation.[6] Merck was to get an exclusive right for commercial production.[32] Schatz was the lead author of the paper on streptomycin discovery with Bugie as the second. Bugie was excluded from the patent due to Waksman's impression that she would "just get married."[16] Years later Bugie told her daughters, "If women's lib had been around, my name would have been on the patent."[34]

Schatz began to feel that Waksman was playing down his (Schatz's) role in the discovery and taking all the credit. In 1949 it was revealed that Waksman, contrary to his public pronouncements, had a private agreement with the foundation giving him 20% of the royalties – which by then had amounted to $350,000 ($3,986,100 adusted for inflation) – and the Rutgers foundation 80%. In March 1950, Schatz, filed a lawsuit against Waksman and the foundation for a share of the royalties and recognition of his role in the discovery of streptomycin.[5] Bugie supported Schatz on the discovery, but did not participate in the royalty matter.[18] Waksman denied receiving any financial benefits. After the court trial on 29 December 1950, the Superior Court of New Jersey issued the verdict in favor of Schatz, concluding that "[Schatz] is entitled to credit legally and scientifically as co-discoverer, with Dr. Selman A. Waksman, of streptomycin."[6]

An out-of-court settlement awarded Schatz $120,000 for the foreign patent rights, and 3% of the royalties, representing about $15,000 per annum for several years.[35] Waksman got 10% and 7% was evenly distributed to all workers in Waksman's lab. With its 80% share, the Rutgers established the Waksman Institute of Microbiology.[18] Schatz was never again able to find work in a top-level microbiology lab.[5]

Nobel Prize and controversy[edit]

In October 1952, Waksman was announced as the sole winner of the 1952 Nobel Prize in Physiology or Medicine "for his discovery of streptomycin, the first antibiotic effective against tuberculosis."[3] The Nobel committee statement given by presenter Arvid Wallgren at the award ceremony in Stockholm on 12 December 1952 was "Selman Waksman, the Caroline Medical Institute has awarded you this year's Nobel Prize for Physiology or Medicine for your ingenious, systematic and successful studies of the soil microbes that led to the discovery of streptomycin"[31] rather than "for the discovery of streptomycin" as the original announcement said.[5] But the official citation was specific "for his discovery".[3]

When Milton Wainwright from Sheffield University arrived at Rutgers and interviewed faculty members for his 1990 book on antibiotics, Miracle Cure, asking questions about Schatz, it piqued the curiosity of some professors, who made their own inquiries and spoke with Schatz. Convinced that he had been the victim of an injustice, a group of professors, including Karl Maramorosch and Douglas Eveleigh, began to lobby for Schatz's rehabilitation, culminating in the 1994 awarding of the Rutgers University Medal, the university's highest honor, to Schatz.[5]

In his accounts on streptomycin discovery, Waksman never mentioned Schatz. When the first clinical trial was performed by Feldman, he did not know that the new drug was discovered by Schatz, and it was much later in Chile (the 1960's) where he met Schatz that the story was brought up in their conversation.[6] The Lancet commented: "The Nobel committee made a considerable mistake by failing to recognise Schatz's contribution."[4]

Discovery of albomycin[edit]

The discovery of streptomycin was followed by that of grisein. Donald M. Reynolds, Schatz and Waksman reported the discovery in 1947.[36] The new antibiotic was isolated from the same bacteria that produced streptomycin. It was not as powerful as streptomycin or streptothricin, but was less toxic and effective against most Gram-negative and Gram-positive bacteria.[37] When other related compounds were discovered from other bacteria, grisein was considered as member of a more specific compound, albomycin.[38] These compounds were later commonly referred to as "Trojan horse" antibiotics for their ability to act as their molecular targets inside the cells.[39][40]

Dental research and controversy[edit]

Since 1945, the US has advocated water fluoridation to prevent tooth decay.[41] Supported by his uncle Martin, Schatz investigated the cause of tooth decay from the mid-1950s.[42] When he began he was surprised to learn that the cause of tooth decay was tacitly assumed to be acidity in the mouth, without any experimental evidence.[7] The acid theory, as it was known, stated that hydrogen ions (which determine pH) are the critical factor for dental health. But his experiments showed that tooth decay occurs regardless of acidity or alklinity.[42] He and his uncle offered a new explanation for tooth decay, the "proteolysis-chelation theory" in 1962.[9] (He later referred to his original 1954 theory as the "chelation theory."[10]) The theory emphasized biochemical reactions over acid demineralization. According to the theory, caries develop as bacteria invade the teeth cavities in the presence of organic compounds (chelating agents) such as sugars, lipids and citrates to break down (proteolyze) the tooth protein (keratin); the process is independent of the pH of the environment.[7]

His findings also led him to oppose the fluoridation of drinking water based on his understanding of the biochemical impact of fluoride on tissue.[11] He challenged the fluoridation of drinking water by public health programs. Reporting in 1967 the "Increased death rate in Chile associated with artificial fluoridation of drinking water, with implications for other latin American countries and for the United States,"[43][44] he further claimed that in Chile water fluoridation not only failed to prevent tooth decay but instead caused increased cancer that led to increased death among people with malnutrition.[45] He also criticized a scientific paper published in 1966 that presented the advantages of water fluoridation in the Curico region of Chile,[46] arguing that the data was incomplete. After reviewing the paper, the US Department of Health Center for Disease Control in Atlanta in 1978 issued a public statement that Schatz's data was improperly analyzed and did not represent the true relationship between water fluoridation and cancer and mortality with the conclusion: "Water fluoridation for the purpose of dental caries prophylaxis poses no hazard relevant to cancer causation."[7] He was severely criticized in 1992 in The New Zealand Medical Journal for bias and publication in an obscure journal.[47] He responded by claiming that the publication was in a legitimate journal,[7] and the critics overlooked the separate publication in The Journal of Nihon University School of Dentistry.[48]

As of 2021, the benefits or dangers of fluoridated water are still not resolved,[41] with recent evidence of its harmful neurological effects.[49]

Personal life[edit]

Schatz's initial interest in soil microbiology stemmed from his intention to become a farmer following his parents. Seeing workers being assaulted by the authorities during the Depression prompted him to lifelong socialism and humanitarianism. He married Vivian Rosenfeld, a student at New Jersey College for Women, in March 1945 and they had two daughters, Linda and Diane.[5][11]

Awards, honors and tributes[edit]

Schatz received honorary degrees from Brazil, Peru, Chile, and the Dominican Republic. On the 50th anniversary of the discovery of streptomycin, in 1994, he was awarded the Rutgers University Medal. The New York Times placed Schatz and Waksman's 1948 streptomycin patent in the top 10 discoveries of the 20th century. The university has made Schatz's basement lab into a museum documenting his and other antibiotic discoveries made at the college.[12]

Legacy[edit]

As a result of the streptomycin controversy, regulations were passed in the US aimed at ensuring graduate students get due recognition and reward for their contributions.[11] Albert Schatz's archives were donated to the Temple University Library.

See also[edit]

References[edit]

  1. ^ Zimmerman, Barry E., David J. (2002). Killer Germs (1 ed.). McGraw-Hill Education;(6 September 2002). p. 48. ISBN 978-0071409261.
  2. ^ a b Margalit Fox (2 February 2005). "Albert Schatz, Microbiologist, Dies at 84". The New York Times. Retrieved 17 August 2013.
  3. ^ a b c "The Nobel Prize in Physiology or Medicine 1952". NobelPrize.org. Retrieved 2021-09-27.
  4. ^ a b The Lancet Infectious Diseases (2005-11-01). "The Nobel cause". The Lancet Infectious Diseases. 5 (11): 665. doi:10.1016/S1473-3099(05)70245-0. PMID 16253880.
  5. ^ a b c d e f g h i j Veronique Mistiaen (2 November 2002). "Time, and the great healer". The Guardian. Retrieved 17 August 2013.
  6. ^ a b c d e f g h i j Schatz, Albert (1993). "The true story of the development of streptomycin". Actinomycetes. 4 (2): 27–39.
  7. ^ a b c d e f g Al Yousef, Sulaiman A. (2021). "The controversial contribution to dental research made by Albert Schatz-Co-discoverer of streptomycin". Saudi Journal of Biological Sciences. 28 (6): 3183–3185. doi:10.1016/j.sjbs.2021.04.029. PMC 8176004. PMID 34121853.
  8. ^ Singh Dewhare, Shivendra (2021). "Drug resistant tuberculosis: Current scenario and impending challenges". Indian Journal of Tuberculosis. 69 (2): 227–233. doi:10.1016/j.ijtb.2021.04.008. PMID 35379406. S2CID 234824255.
  9. ^ a b Schatz, A.; Martin, J. J. (1962). "The proteolysis-chelation theory of dental caries". Journal of the American Dental Association. 65 (3): 368–375. doi:10.14219/jada.archive.1962.0265. ISSN 0002-8177. PMID 14498070.
  10. ^ a b Schatz, A.; Martin, J. J.; Schatz, V. (1972). "The chelation and proteolysis-chelation theories of dental caries: their origin, evolution and philosophy". The New York State Dental Journal. 38 (5): 285–295. PMID 4501933.
  11. ^ a b c d Milton Wainwright (4 February 2005). "Albert Schatz: Co-discoverer of streptomycin". The Independent. Archived from the original on 2014-01-13. Retrieved 17 August 2013.
  12. ^ a b "Albert Schatz, co-discoverer of streptomycin, dies at 84". Rutgers Focus. Rutgers University Relations. 21 February 2005. Archived from the original on 22 July 2012. Retrieved 15 August 2013.
  13. ^ Heilman, D. H. (1945). "Cytotoxicity of Streptomycin and Streptothricin". Experimental Biology and Medicine. 60 (3): 365–367. doi:10.3181/00379727-60-15191. PMID 21010293. S2CID 38003542.
  14. ^ a b Waksman, Selman A.; Schatz, Albert (1945). "Streptomycin–origin, nature, and properties". Journal of the American Pharmaceutical Association. 34 (11): 273–291. doi:10.1002/jps.3030341102.
  15. ^ Waksman, Selman A.; Woodruff, H. Boyd (1942-02-01). "Streptothricin, a New Selective Bacteriostatic and Bactericidal Agent, Particularly Active Against Gram-Negative Bacteria". Proceedings of the Society for Experimental Biology and Medicine. 49 (2): 207–210. doi:10.3181/00379727-49-13515. S2CID 87684588.
  16. ^ a b Eveleigh, Douglas E.; Bennett, Joan W. (2018-05-01), Whitaker; Barton (eds.), "Women Microbiologists at Rutgers in the Early Golden Age of Antibiotics", Women in Microbiology, American Society of Microbiology, pp. 317–329, doi:10.1128/9781555819545.ch34, ISBN 978-1-55581-953-8, retrieved 2021-09-27
  17. ^ a b Schatz, A.; Bugle, E.; Waksman, S. A. (1944). "Streptomycin, a Substance Exhibiting Antibiotic Activity Against Gram-Positive and Gram-Negative Bacteria.*". Experimental Biology and Medicine. 55 (1): 66–69. doi:10.3181/00379727-55-14461. S2CID 33680180.
  18. ^ a b c Schatz, Albert; Bugie, Elizabeth; Waksman, Selman A (2005). Hanssen, Arle (ed.). "The Classic: Streptomycin, a Substance Exhibiting Antibiotic Activity against Gram-Positive and Gram-Negative Bacteria". Clinical Orthopaedics and Related Research. 437 (1): 3–6. doi:10.1097/01.blo.0000175887.98112.fe. PMID 16056018.
  19. ^ Koch, Anastasia; Mizrahi, Valerie (2018). "Mycobacterium tuberculosis". Trends in Microbiology. 26 (6): 555–556. doi:10.1016/j.tim.2018.02.012. PMID 29580884. S2CID 4314953.
  20. ^ Jones, D.; Metzger, H. J.; Schatz, A.; Waksman, S. A. (1944). "Control of gram-negative bacteria in experimental animals by streptomycin". Science. 100 (2588): 103–105. doi:10.1126/science.100.2588.103. PMID 17788929.
  21. ^ Schatz, A.; Waksman, S. A. (1944). "Effect of Streptomycin and Other Antibiotic Substances upon Mycobacterium tuberculosis and Related Organisms". Experimental Biology and Medicine. 57 (2): 244–248. doi:10.3181/00379727-57-14769. S2CID 85041638.
  22. ^ Schatz, A.; Waksman, S. A. (1945). "Strain Specificity and Production of Antibiotic Substances: IV. Variations Among Actionomycetes, with Special Reference to Actinomyces Griseus". Proceedings of the National Academy of Sciences of the United States of America. 31 (5): 129–137. Bibcode:1945PNAS...31..129S. doi:10.1073/pnas.31.5.129. PMC 1078778. PMID 16578147.
  23. ^ Waksman, S. A.; Reilly, H. C.; Schatz, A. (1945). "Strain Specificity and Production of Antibiotic Substances: V. Strain Resistance of Bacteria to Antibiotic Substances, Especially to Streptomycin". Proceedings of the National Academy of Sciences of the United States of America. 31 (6): 157–164. Bibcode:1945PNAS...31..157W. doi:10.1073/pnas.31.6.157. PMC 1078787. PMID 16578153.
  24. ^ Waksman, S. A.; Schatz, A. (1945). "Strain Specificity and Production of Antibiotic Substances: VI. Strain Variation and Production of Streptothricin by Actinomyces Lavendulae". Proceedings of the National Academy of Sciences of the United States of America. 31 (7): 208–214. Bibcode:1945PNAS...31..208W. doi:10.1073/pnas.31.7.208. PMC 1078802. PMID 16578164.
  25. ^ Waksman, Selman A.; Schatz, Albert; Reynolds, Donald M. (2010) [1946]. "Production of antibiotic substances by actinomycetes". Annals of the New York Academy of Sciences. 1213: 112–124. doi:10.1111/j.1749-6632.2010.05861.x. PMID 21175680. S2CID 19208692.
  26. ^ Feldman, William H.; Hinshaw, H. Corwin; Mann, Frank C. (2019) [1945]. "Streptomycin in Experimental Tuberculosis". American Review of Tuberculosis. 52 (4): 269–298. doi:10.1164/art.1945.52.4.269 (inactive 31 July 2022).{{cite journal}}: CS1 maint: DOI inactive as of July 2022 (link)
  27. ^ Pfuetze, K. H.; Pyle, M. M.; Hinshaw, H. C.; Feldman, W. H. (1955). "The first clinical trial of streptomycin in human tuberculosis". American Review of Tuberculosis. 71 (5): 752–754. doi:10.1164/artpd.1955.71.5.752 (inactive 31 July 2022). PMID 14361985.{{cite journal}}: CS1 maint: DOI inactive as of July 2022 (link)
  28. ^ Anderson, Donald G.; Jewell, Marjorie (1945). "The Absorption, Excretion and Toxicity of Streptomycin in Man". New England Journal of Medicine. 233 (17): 485–491. doi:10.1056/NEJM194510252331701.
  29. ^ Pfuetze, K. H.; Glover, R. P. (1946). "Clinical use of streptomycin in the treatment of tuberculosis". Diseases of the Chest. 12 (6): 515–520. doi:10.1378/chest.12.6.515. PMID 20274642.
  30. ^ Hinshaw, H. C.; Feldman, W. H.; Pfuetze, K. H. (1946). "Streptomycin in treatment of clinical tuberculosis". American Review of Tuberculosis. 54 (3): 191–203. doi:10.1164/art.1946.54.3.191 (inactive 31 July 2022). PMID 20274624.{{cite journal}}: CS1 maint: DOI inactive as of July 2022 (link)
  31. ^ a b c Woodruff, H. Boyd (2014). "Selman A. Waksman, winner of the 1952 Nobel Prize for physiology or medicine". Applied and Environmental Microbiology. 80 (1): 2–8. Bibcode:2014ApEnM..80....2W. doi:10.1128/AEM.01143-13. PMC 3911012. PMID 24162573.
  32. ^ a b Santesmases, María Jesús (2011). "Screening antibiotics: industrial research by CEPA and Merck in the 1950s". Dynamis. 31 (2): 407–427. doi:10.4321/S0211-95362011000200008. PMID 22332466.
  33. ^ "Selman A. Waksman". Chemotherapy. 13 (3): 129–132. 1968. doi:10.1159/000220540.
  34. ^ Angelova, Lidiya (2018-08-08). "Elizabeth Bugie – the invisible woman in the discovery of streptomycin". The Scientista Foundation. Retrieved 2021-09-27.{{cite web}}: CS1 maint: url-status (link)
  35. ^ "Dr. Schatz Wins 3% of Royalty; Named Co-Finder of Streptomycin; Key Figures in Streptomycin Discovery Suit". New York Times. 30 December 1950. Retrieved 17 August 2013.
  36. ^ Reynolds, D. M.; Schatz, A.; Waksman, S. A. (1947). "Grisein, a New Antibiotic Produced by a Strain of Streptomyces griseus". Experimental Biology and Medicine. 64 (1): 50–54. doi:10.3181/00379727-64-15695. ISSN 1535-3702. PMID 20285459. S2CID 35866714.
  37. ^ Reynolds, D. M.; Waksman, S. A. (1948). "Grisein, an Antibiotic Produced by Certain Strains of Streptomyces griseus". Journal of Bacteriology. 55 (5): 739–752. doi:10.1128/jb.55.5.739-752.1948. PMC 518506. PMID 16561513.
  38. ^ Stapley, E. O.; Ormond, R. E. (1957). "Similarity of albomycin and grisein". Science. 125 (3248): 587–589. Bibcode:1957Sci...125..587S. doi:10.1126/science.125.3248.587. PMID 13409012. S2CID 12860105.
  39. ^ Lin, Zihua; Xu, Xiaobo; Zhao, Sheng; Yang, Xiaohong; Guo, Jian; Zhang, Qun; Jing, Chunmei; Chen, Shawn; He, Yun (2018). "Total synthesis and antimicrobial evaluation of natural albomycins against clinical pathogens". Nature Communications. 9 (1): 3445. Bibcode:2018NatCo...9.3445L. doi:10.1038/s41467-018-05821-1. PMC 6123416. PMID 30181560.
  40. ^ Travin, Dmitrii Y.; Severinov, Konstantin; Dubiley, Svetlana (2021). "Natural Trojan horse inhibitors of aminoacyl-tRNA synthetases". RSC Chemical Biology. 2 (2): 468–485. doi:10.1039/D0CB00208A. PMC 8323819. PMID 34382000.
  41. ^ a b Stansfield, Brian K. (2021). "Invitation for controversy". Pediatric Research. 90 (4): 706–707. doi:10.1038/s41390-021-01651-y. PMID 34272491.
  42. ^ a b Karlson, K. E.; Martin, J. J.; Schatz, A. (1956). "Trace element stimulation of keratin (hair) degradation by oral keratinolytic microflora". Experientia. 12 (8): 308–309. doi:10.1007/BF02159627. PMID 13356812. S2CID 21867147.
  43. ^ Jones, Graeme (2001). "Water fluoridation". BMJ. 322 (7300): 1486, author reply 1487–8. doi:10.1136/bmj.322.7300.1486. PMC 1120532. PMID 11430366.
  44. ^ "Notice 241287 - Increased death rate in Chile associated with artificial fluoridation of drinking water, with implications for other latin American countries and for the United States". www.bibliotheque.assnat.qc.ca. Retrieved 2021-09-26.
  45. ^ Schatz, A. (1996). "Low-Level Fluoridation and Low-Level Radiation-Two Case Histories of Misconduct in Science" (PDF). www.talkingaboutthescience.com. Archived (PDF) from the original on 2021-09-26. Retrieved 2021-09-26.
  46. ^ Briner, A.; Carmona, I. (1966). "Fluoridation and mortality in Chile". Odontologia Chilena. 15 (83): 7–21. ISSN 0029-8417. PMID 5230728.
  47. ^ Mitchell, E. A. (1992-03-11). "Cot death and fluoridation". The New Zealand Medical Journal. 105 (929): 90. ISSN 0028-8446. PMID 1545951.
  48. ^ Schatz, Albert (1967). "The Failure of Fluoridation in Chile. A Critical Analysis after Eleven Years". The Journal of Nihon University School of Dentistry. 9 (4): 209–212. doi:10.2334/josnusd1959.9.209. PMID 4386161.
  49. ^ Till, Christine; Green, Rivka (2020). "Controversy: The evolving science of fluoride: when new evidence doesn't conform with existing beliefs". Pediatric Research. 90 (5): 1093–1095. doi:10.1038/s41390-020-0973-8. PMID 32443137.
  50. ^ IPNI.  A.Schatz.

Further reading[edit]

External links[edit]